Day One Biopharmaceuticals (DAWN) delisted from Nasdaq; Exchange cites compliance

Rhea-AI Filing Summary

Day One Biopharmaceuticals, Inc. notified the Nasdaq Stock Market LLC of the removal of its Common Stock from listing and registration under Section 12(b) via Form 25. The Exchange states it complied with 17 CFR 240.12d2-2 and the issuer complied with the Exchange's rules governing voluntary withdrawal.

Insights

Exchange Compliance Analyst

Nasdaq filed a Form 25 to delist Day One Biopharmaceuticals' common shares; both parties assert rule compliance.

The filing records a formal removal from Nasdaq listing for the issuer's Common Stock and cites 17 CFR 240.12d2-2. The Exchange certifies it has reasonable grounds and that procedural steps under the cited rule were followed.

Timing and consequences for shareholders (transfer to another venue, cessation of exchange trading) are not specified in the excerpt; subsequent filings or broker notices will reflect next steps.

Key Figures

Commission File Number: 001-40431 Expires: March 31, 2018 Telephone: (650) 484-0899 +2 more

5 metrics

Commission File Number 001-40431 Form 25 cover line

Expires March 31, 2018 form header expiration date

Telephone (650) 484-0899 Issuer principal executive offices

Zip code 94005 Issuer address, Brisbane, California

CFR citation 17 CFR 240.12d2-2 rule governing removal/withdrawal referenced in filing

Key Terms

Form 25, 17 CFR 240.12d2-2, voluntary withdrawal

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b)"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

voluntary withdrawal regulatory

"the Issuer has complied with its rules...governing the voluntary withdrawal"

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-40431

Issuer:	Day One Biopharmaceuticals, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	1800 Sierra Point Parkway
	Suite 200
	Brisbane	CALIFORNIA	94005
Telephone number:					(650) 484-0899

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-04-23	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Day One Biopharmaceuticals (DAWN) filing Form 25 mean?

It means DAWN's Common Stock is being removed from Nasdaq listing. The Exchange certified compliance with 17 CFR 240.12d2-2, and the issuer complied with Nasdaq rules for voluntary withdrawal; further transaction and trading details are provided in subsequent exchange or broker notices.

Will DAWN shares still trade after the Form 25 delisting?

Delisting from Nasdaq does not automatically stop all trading. Shares often move to over-the-counter venues or cease exchange trading; the filing excerpt does not state the next trading venue or effective date for cessation of Nasdaq trading.

Who signed the Form 25 on behalf of Nasdaq for DAWN?

The Form 25 was signed by Tara Petta, AVP, on behalf of Nasdaq. The filing certifies the Exchange has reasonable grounds to believe it met the requirements for submitting the Form 25 under the Exchange Act.

Which regulatory provision does the Form 25 for DAWN cite?

The filing cites 17 CFR 240.12d2-2. That rule governs strike-offs and withdrawals from listing/registration; the Exchange also referenced compliance with subsections (a)(1)–(a)(4) in the excerpt.